

FOR IMMEDIATE RELEASE

HYGEIA Group and DELTA HEALTH Forge Strategic Alliance to Accelerate Clinical Trials in Turkiye, Targeting the Biotech "Execution Gap"

Partnership combines HYGEIA's investment-grade operational oversight with DELTA HEALTH's rapid-deployment clinical infrastructure to de-risk global drug development.

TORONTO, Canada & ISTANBUL, Turkiye - February 24, 2026

HYGEIA Group Inc., a specialized operational partner for biotech venture capital, private equity and life sciences firms, and DELTA HEALTH GROUP, a global healthcare organization and clinical trial network, today announced the signing of a Collaboration Agreement to establish a high-velocity clinical deployment channel in Turkiye.

The collaboration addresses a critical bottleneck in modern drug development: the **"execution gap"** where promising therapeutics fail not due to science, but due to operational delays and enrollment failures. By integrating HYGEIA's strategic oversight with DELTA HEALTH's on-the-ground capabilities, including its bilateral partnership with the Ministry of Health Turkiye (TITCK), the alliance offers biotech sponsors a **"rescue strategy"** for stalled clinical trials and a **primary Ex-USA strategy** for rapid enrollment.

Strategic Expansion into Turkiye Under the terms of the agreement, DELTA HEALTH GROUP will provide sponsors with access to at least (5) operational and dedicated clinical research sites in Turkiye within the next three to four months. These sites will be specifically optimized for complex therapeutic areas where Turkiye offers significant competitive advantages, including vast populations of treatment-naive patients.

In addition to a diverse range of therapeutic areas, priority indications for the new sites include:

- Precision Oncology & Cancer Genomics
- Cell & Gene Therapy
- Rare Diseases / Orphan Indications

Executive Commentary

"Biotech investors are increasingly frustrated by the capital trapped in operational inefficiencies," said **Amin Jagani, Managing Partner of HYGEIA Group**. "Our mandate is to protect their investment by ensuring execution matches the science. By partnering with DELTA HEALTH, we are securing a direct, reliable channel to high-quality clinical data. Dr. Kizilbash's

team in Turkiye offers the speed and patient access that North American sites simply cannot match right now, effectively de-risking the path to regulatory approval."

"We are aligned with HYGEIA's mission to bring operational transparency and speed to the clinical trial landscape," said **Dr. Arshi Kizilbash, CEO of DELTA HEALTH GROUP**. "Turkiye represents an underutilized powerhouse for clinical research, offering high-quality medical infrastructure and eager patient populations. This partnership allows us to deploy our US FDA vetted 'A-Team' to serve global sponsors, turning Turkiye into a premier destination for 'rescue' as well as 'primary' enrollment strategies."

About HYGEIA Group Inc. HYGEIA Group Inc. (a subsidiary of Alpha Gainvest, Inc.) is a specialized investment advisory and biotech consulting firm serving Life Sciences Venture Capital and Private Equity funds. HYGEIA provides deep operational due diligence and embedded C-suite leadership to diagnose risks and stabilize portfolio companies. Their "Sprint" model and investor-focused methodology ensure that capital is deployed effectively to maximize asset value. **Website:** www.hygeiagroupinc.com

About DELTA HEALTH GROUP DELTA HEALTH is an international healthcare conglomerate providing a comprehensive portfolio of clinical drug development expertise and a worldwide network of premier clinical trial investigative sites. With a focus on connecting medical innovations to patient populations, DELTA HEALTH GROUP specializes in rapid site deployment and late-stage clinical execution, supported by an international telemedicine division. **Website:** www.deltahealth.org

Media Contacts:

HYGEIA Group Inc. Media Relations Email: info@hygeiagroupinc.com

DELTA HEALTH Corporate Communications Email: info@deltahealth.org.